EphrinA1 Is Released in Three Forms from Cancer Cells by Matrix Metalloproteases

REFERENCES

• Adibhatla RM, Hatcher JF. 2008. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol. Disord. Drug Targets 7:243–253.
   PubMed Web of Science ®Google Scholar
• Alford S, et al. 2010. Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells. Cancer Cell Int. 10:41.
   PubMedGoogle Scholar
• Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL. 2007. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp. Cell Res. 313:4170–4179.
   PubMedGoogle Scholar
• Anand M, Van Meter T, Fillmore H. 2011. Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J. Neurooncol. 104:679–687.
   PubMed Web of Science ®Google Scholar
• Bartley TD, et al. 1994. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 368:558–560.
   PubMed Web of Science ®Google Scholar
• Beauchamp A, Debinski W. 2012. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin. Cell Dev. Biol. 23:109–115.
   PubMed Web of Science ®Google Scholar
• Beckmann MP, et al. 1994. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J. 13:3757–3762.
   PubMed Web of Science ®Google Scholar
• Bong Y-S, et al. 2007. ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc. Natl. Acad. Sci. U. S. A. 104:17305–17310.
   PubMed Web of Science ®Google Scholar
• Brinckerhoff CE, Rutter JL, Benbow U. 2000. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 6:4823–4830.
   PubMed Web of Science ®Google Scholar
• Choe G, et al. 2002. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8:2894–2901.
   PubMed Web of Science ®Google Scholar
• Cui X-D, et al. 2010. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int. J. Cancer 126:940–949.
   PubMed Web of Science ®Google Scholar
• Davis S, et al. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266:816–819.
   PubMed Web of Science ®Google Scholar
• Davy A, et al. 1999. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 13:3125–3135.
   PubMed Web of Science ®Google Scholar
• Debinski W. 2008. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev. Neurother. 8:515–517.
   PubMedGoogle Scholar
• Dunaway CM, et al. 2011. Cooperative signaling between Slit2 and ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol. Cell. Biol. 31:404–416.
   PubMedGoogle Scholar
• Egea J, et al. 2005. Regulation of EphA4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron 47:515–528.
   PubMed Web of Science ®Google Scholar
• Finne EF, Aasheim MEHC. 2004. A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a. Biochem. J. 379(Pt 1):39–46.
   PubMedGoogle Scholar
• Gale NW, Yancopoulos GD. 1997. Ephrins and their receptors: a repulsive topic? Cell Tissue Res. 290:227–241.
   PubMed Web of Science ®Google Scholar
• Gale NW. 1996. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17:9–19.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. 2011. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27.
   PubMed Web of Science ®Google Scholar
• Hagemann C, Anacker J, Haas S, Riesner D, Schömig B, Ernestus R-I, Vince GH. 2010. Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res. Notes 3:293.
   PubMedGoogle Scholar
• Hattori M, Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289:1360–1365.
   PubMed Web of Science ®Google Scholar
• Himanen J-P, et al. 2004. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 7:501–509.
   PubMed Web of Science ®Google Scholar
• Himanen J-P, et al. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933–938.
   PubMed Web of Science ®Google Scholar
• Himanen J-P, Saha N, Nikolov DB. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 19:534–542.
   PubMed Web of Science ®Google Scholar
• Himanen JP, et al. 2010. Architecture of Eph receptor clusters. Proc. Natl. Acad. Sci. U. S. A. 107:10860–10865.
   PubMedGoogle Scholar
• Himanen JP, et al. 2009. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep. 10:722–728.
   PubMedGoogle Scholar
• Holen HL, et al. 2008. Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J. Leukoc. Biol. 84:1183–1191.
   PubMedGoogle Scholar
• Holzman LB, Marks RM, Dixit VM. 1990. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol. Cell. Biol. 10:5830–5838.
   PubMed Web of Science ®Google Scholar
• Ikezawa H. 2002. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25:409–417.
   PubMed Web of Science ®Google Scholar
• Irie N, et al. 2009. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J. Biol. Chem. 284:14637–14644.
   PubMedGoogle Scholar
• Janes PW, et al. 2005. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123:291–304.
   PubMed Web of Science ®Google Scholar
• Janes PW, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol. 7:e1000215. https://doi.org/10.1371/journal.pbio.1000215.
   PubMedGoogle Scholar
• Klein T, Bischoff R. 2011. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41:271–290.
   PubMed Web of Science ®Google Scholar
• Krane SM. 2001. Petulant cellular acts: destroying the ECM rather than creating it. J. Clin. Invest. 107:31–32.
   PubMed Web of Science ®Google Scholar
• Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3:475–486.
   PubMed Web of Science ®Google Scholar
• Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. 1998. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am. J. Pathol. 153:429–437.
   PubMed Web of Science ®Google Scholar
• Lee H-S, et al. 2006. Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. Nat. Cell Biol. 8:55–63.
   PubMed Web of Science ®Google Scholar
• Leeman MF, Curran S, Murray GI. 2002. The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 37:149–166.
   PubMed Web of Science ®Google Scholar
• Levicar N, Nutall RK, Lah TT. 2003. Proteases in brain tumour progression. Acta Neurochir. 145:825–838.
   PubMed Web of Science ®Google Scholar
• Lim Y-S, et al. 2008. p75NTR mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59:746–758.
   PubMedGoogle Scholar
• Lin K-T, Sloniowski S, Ethell DW, Ethell IM. 2008. Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J. Biol. Chem. 283:28969–28979.
   PubMedGoogle Scholar
• Lu D-Y, Leung Y-M, Cheung C-W, Chen Y-R, Wong K-L. 2010. Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem. Pharmacol. 80:1201–1209.
   PubMedGoogle Scholar
• Macrae M, et al. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8:111–118.
   PubMed Web of Science ®Google Scholar
• Marler K, Poopalasundaram S, Broom E, Wentzel C, Drescher U. 2010. Pro-neurotrophins secreted from retinal ganglion cell axons are necessary for ephrinA-p75NTR-mediated axon guidance. Neural Dev. 5:30.
   PubMedGoogle Scholar
• Marler KJ, et al. 2008. A TrkB/EphrinA interaction controls retinal axon branching and synaptogenesis. J. Neurosci. 28:12700–12712.
   PubMed Web of Science ®Google Scholar
• Miao H, Burnett E, Kinch M, Simon E, Wang B. 2000. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2:62–69.
   PubMed Web of Science ®Google Scholar
• Mott JD, Werb Z. 2004. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16:558–564.
   PubMed Web of Science ®Google Scholar
• Murai KK, Pasquale EB. 2003. ‘Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 116:2823–2832.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2008. Eph-Ephrin bidirectional signaling in physiology and disease. Cell 133:38–52.
   PubMed Web of Science ®Google Scholar
• Pezzato E, et al. 2003. Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (minus)epigallocatechin-3-gallate. J. Leukoc. Biol. 74:88–94.
   PubMed Web of Science ®Google Scholar
• Pullen NA, Anand M, Cooper PS, Fillmore HL. 2012. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma. J. Neurooncol. 106:461–471.
   PubMed Web of Science ®Google Scholar
• Raithatha SA, et al. 2000. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol. 2:145–150.
   PubMed Web of Science ®Google Scholar
• Roy R, Yang J, Moses MA. 2009. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27:5287–5297.
   PubMed Web of Science ®Google Scholar
• Saunders WB, Bayless KJ, Davis GE. 2005. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J. Cell Sci. 118:2325–2340.
   PubMed Web of Science ®Google Scholar
• Shao H, Pandey A, O'Shea KS, Seldin M, Dixit VM. 1995. Characterization of B61, the ligand for the Eck receptor protein-tyrosine kinase. J. Biol. Chem. 270:5636–5641.
   PubMedGoogle Scholar
• Singla N, et al. 2010. Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations. Biochem. Biophys. Res. Commun. 399:555–559.
   PubMed Web of Science ®Google Scholar
• Stojic J, et al. 2008. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci. Res. 60:40–49.
   PubMed Web of Science ®Google Scholar
• Stupp R, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987–996.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sasaki K, Kamata R, Sakai R. 2007. The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells. J. Cell Sci. 120:2179–2189.
   PubMedGoogle Scholar
• Vearing CJ, Lackmann M. 2005. “Eph receptor signalling; dimerisation just isn't enough.” Growth Factors 23:67–76.
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Riese DJ, Kinch MS. 2002. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. 1:79–87.
   PubMed Web of Science ®Google Scholar
• Wang LF, et al. 2008. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol. Rep. 19:151–156.
   PubMed Web of Science ®Google Scholar
• Wei S, et al. 2010. ADAM13 induces cranial neural crest by cleaving class B ephrins and regulating Wnt signaling. Dev. Cell 19:345–352.
   PubMed Web of Science ®Google Scholar
• Winslow JW, et al. 1995. Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron 14:973–981.
   PubMed Web of Science ®Google Scholar
• Wykosky J, Debinski W. 2008. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6:1795–1806.
   PubMed Web of Science ®Google Scholar
• Wykosky J, Gibo DM, Debinski W. 2007. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol. Cancer Ther. 6:3208–3218.
   PubMed Web of Science ®Google Scholar
• Wykosky J, Gibo DM, Stanton C, Debinski W. 2005. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3:541–551.
   PubMed Web of Science ®Google Scholar
• Wykosky J, Gibo DM, Stanton C, Debinski W. 2008. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res. 14:199–208.
   PubMed Web of Science ®Google Scholar
• Wykosky J, et al. 2008. Soluble monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27:7260–7273.
   PubMed Web of Science ®Google Scholar
• Zhang Y, et al. 2011. Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol. Res. Pract. 207:24–29.
   PubMed Web of Science ®Google Scholar